- Home
- Eurosurveillance
- Previous Issues
- Volume 29, Issue 3, 18/Jan/2024
Eurosurveillance - Volume 29, Issue 3, 18 January 2024
Volume 29, Issue 3, 2024
- Rapid communication
-
-
-
A case of swine influenza A(H1N2)v in England, November 2023
Jade Cogdale , Beatrix Kele , Richard Myers , Ruth Harvey , Abi Lofts , Tanya Mikaiel , Katja Hoschler , Ashley C Banyard , Joe James , Benjamin C Mollett , Alexander MP Byrne , Jamie Lopez-Bernal , Conall H Watson , Meera Chand , William Welfare , Deborah A Williamson , Isabel Oliver , Simon Padfield , Andrew Lee , Suzanne Calvert , Martin A Bewley , Louise Wallace , Simon deLusignan , Nicola S Lewis , Ian H Brown , Maria Zambon and on behalf of the Influenza A(H1N2)v Incident Management TeamUnder International Health Regulations from 2005, a human infection caused by a novel influenza A virus variant is considered an event that has potential for high public health impact and is immediately notifiable to the World Health Organisation. We here describe the clinical, epidemiological and virological features of a confirmed human case of swine influenza A(H1N2)v in England detected through community respiratory virus surveillance. Swabbing and contact tracing helped refine public health risk assessment, following this unusual and unexpected finding.
-
-
-
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
Liliana Antunes , Clara Mazagatos , Iván Martínez-Baz , Verónica Gomez , Maria-Louise Borg , Goranka Petrović , Róisín Duffy , François E Dufrasne , Ralf Dürrwald , Mihaela Lazar , Ligita Jancoriene , Beatrix Oroszi , Petr Husa , Jennifer Howard , Aryse Melo , Francisco Pozo , Gloria Pérez-Gimeno , Jesús Castilla , Ausenda Machado , Aušra Džiugytė , Svjetlana Karabuva , Margaret Fitzgerald , Sébastien Fierens , Kristin Tolksdorf , Silvia-Odette Popovici , Auksė Mickienė , Gergő Túri , Lenka Součková , Nathalie Nicolay , Angela MC Rose and on behalf of the European Hospital Vaccine Effectiveness GroupWe conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
-
- Top
-
- Outbreaks
-
-
-
Ralstonia pickettii bloodstream infections with potential genomic link to internationally distributed contaminated saline solution, Germany, October 2023
Ralstonia pickettii is a Gram-negative rod which may cause invasive infections when they contaminate liquid medical products. After R. pickettii was detected in blood cultures and a stem cell product from three patients in a tertiary care hospital in Germany, whole genome sequencing of these three isolates and two water isolates from the environment was performed. Core genome multilocus sequence typing analysis showed that the three patient isolates were closely related and there was a large distance to the environmental isolates. In a genomic comparison, the patients’ isolates were distantly related to an R. pickettii strain from a cluster in Australia suspected to be caused by contaminated saline produced in India, while all liquid medical products with a link to all patients were produced in Europe or the United States. Our data point towards an ongoing risk by an unknown common source that could be traced back to medical products contaminated with R. pickettii and potentially distributed worldwide. Investigating invasive R. pickettii infections, identifying and testing medical products administered to the patients and timely whole genome sequencing may help identify the exact source of this potentially global outbreak.
-
- Top
-
- Research
-
-
-
Early-onset group B streptococcal infections in five Nordic countries with different prevention policies, 1995 to 2019
Verna Björklund , Harri Saxén , Olof Hertting , Emma Louise Malchau Carlsen , Steen Hoffmann , Stellan Håkansson , Valtýr Stefánsson Thors , Ásgeir Haraldsson , Anne Karin Brigtsen , Henrik Döllner , Heikki Huhtamäki , Tytti Pokka , Terhi Susanna Ruuska and Nordic Research Network for Paediatric Infectious Diseases Study Group (NORDPID)BackgroundNeonatal early-onset disease caused by group B Streptococcus (GBS) is a leading cause of infant morbidity. Intrapartum antibiotic prophylaxis (IAP) is effective in preventing early-onset GBS disease, but there is no agreement on the optimal strategy for identifying the pregnant women requiring this treatment, and both risk-based prophylaxis (RBP) and GBS screening-based prophylaxis (SBP) are used.
AimThe aim of this study was to evaluate the effect of SBP as a public health intervention on the epidemiology of early-onset GBS infections.
MethodsIn 2012, Finland started the universal SBP, while Denmark, Iceland, Norway and Sweden continued with RBP. We conducted an interrupted time series analysis taking 2012 as the intervention point to evaluate the impact of this intervention. The incidences of early- and late-onset GBS infections during Period I (1995–2011) and Period II (2012–2019) were collected from each national register, covering 6,605,564 live births.
ResultsIn Finland, a reduction of 58% in the incidence of early-onset GBS disease, corresponding to an incidence rate ratio (IRR) of 0.42 (95% CI: 0.34–0.52), was observed after 2012. At the same time, the pooled IRR of other Nordic countries was 0.89 (95% CI: 0.80–1.0), specifically 0.89 (95% CI: 0.70–1.5) in Denmark, 0.34 (95% CI: 0.15–0.81) in Iceland, 0.72 (95% CI: 0.59–0.88) in Norway and 0.97 (95% CI: 0.85–1.1) in Sweden.
ConclusionsIn this ecological study of five Nordic countries, early-onset GBS infections were approximately halved following introduction of the SBP approach as compared with RBP.
-
-
-
Time trends and modifiable factors of COVID-19 contact tracing coverage, Geneva, Switzerland, June 2020 to February 2022
BackgroundContact tracing was one of the central non-pharmaceutical interventions implemented worldwide to control the spread of SARS-CoV-2, but its effectiveness depends on its ability to detect contacts.
AimEvaluate the proportion of secondary infections captured by the contact tracing system in Geneva.
MethodsWe analysed 166,892 concomitant infections occurring at the same given address from June 2020 until February 2022 using an extensive operational database of SARS-CoV-2 tests in Geneva. We used permutation to compare the total number of secondary infections occurring at the same address with that reported through manual contact tracing.
ResultsContact tracing captured on average 41% of secondary infections, varying from 23% during epidemic peaks to 60% during low epidemic activity. People living in wealthy neighbourhoods were less likely to report contacts (odds ratio (OR): 1.6). People living in apartment buildings were also less likely to report contacts than those living in a house (OR: 1.1–3.1) depending on the SARS-CoV-2 variant, the building size and the presence of shops. This under-reporting of contacts in apartment buildings decreased during periods of mandatory wearing of face masks and restrictions on private gatherings.
ConclusionContact tracing alone did not detect sufficient secondary infections to reduce the spread of SARS-CoV-2. Campaigns targeting specific populations, such as those in wealthy areas or apartment buildings, could enhance coverage. Additionally, measures like wearing face masks, improving ventilation and implementing restrictions on gatherings should also be considered to reduce infections resulting from interactions that may not be perceived as high risk.
-
- Top
-
- Author's correction
-
Volumes & issues
-
Volume 29 (2024)
-
Volume 28 (2023)
-
Volume 27 (2022)
-
Volume 26 (2021)
-
Volume 25 (2020)
-
Volume 24 (2019)
-
Volume 23 (2018)
-
Volume 22 (2017)
-
Volume 21 (2016)
-
Volume 20 (2015)
-
Volume 19 (2014)
-
Volume 18 (2013)
-
Volume 17 (2012)
-
Volume 16 (2011)
-
Volume 15 (2010)
-
Volume 14 (2009)
-
Volume 13 (2008)
-
Volume 12 (2007)
-
Volume 11 (2006)
-
Volume 10 (2005)
-
Volume 9 (2004)
-
Volume 8 (2003)
-
Volume 7 (2002)
-
Volume 6 (2001)
-
Volume 5 (2000)
-
Volume 4 (1999)
-
Volume 3 (1998)
-
Volume 2 (1997)
-
Volume 1 (1996)
-
Volume 0 (1995)
Most Read This Month
-
-
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Victor M Corman , Olfert Landt , Marco Kaiser , Richard Molenkamp , Adam Meijer , Daniel KW Chu , Tobias Bleicker , Sebastian Brünink , Julia Schneider , Marie Luisa Schmidt , Daphne GJC Mulders , Bart L Haagmans , Bas van der Veer , Sharon van den Brink , Lisa Wijsman , Gabriel Goderski , Jean-Louis Romette , Joanna Ellis , Maria Zambon , Malik Peiris , Herman Goossens , Chantal Reusken , Marion PG Koopmans and Christian Drosten
-
- More Less